Welcome To The Resverlogix HUB On AGORACOM
**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Trial and a Phase 2 Kidney Trial is Planned for 2017**
We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies, said Dr. Chamberland, Chief Science Officer.
DONALD J. MCCAFFREY
President and CEO, Co-Founder
Donald McCaffrey is President & Chief Executive Officer (CEO) of Resverlogix Corp. He has over 35 years of business experience including 15 years of drug discovery & development. Donald has led Resverlogix through significant changes and achievements from its initial days as a private company to becoming a TSX listed company. He has personally raised over $300 million for research and clinical development in the areas of cardiovascular disease, diabetes mellitus, chronic kidney disease, Orphan diseases, Alzheimer’s disease and other serious indications. In addition to garnering appropriate financing for Resverlogix’s aggressive development plan, Donald has strategically directed the company in its continued partnering discussions with global pharmaceutical companies, establishing one of the largest China biotech partnerships to date with Hepalink Pharmaceuticals.
Donald’s expertise in corporate operations has attracted an international team of experts in research, development, and corporate affairs to Resverlogix. Lead drug, apabetalone (RVX-208) has now commenced a Phase 3 clinical trial called 'BETonMACE.' Apabetalone is a regulated drug which has the potential to be first in a new class of drugs for the reduction in Major Adverse Cardiac Events (MACE).
As President and CEO of Resverlogix, Mr. McCaffrey spearheaded the development and spin-out of Resverlogix’s subsidiary RVX Therapeutics Inc. to Zenith Epigenetics Corp.. Zenith Epigenetics is developing bromodomain (BET) inhibitors (BRD4) for the treatment of cancer and autoimmune disorders and has an estimated enterprise value of $100 million. Mr. McCaffrey is the current President and CEO of Zenith Epigenetics and has assembled a world class Oncology team to further the development of this program. Mr. McCaffrey is also the Chairman of the Board of Directors for Zenith Epigenetics.
Donald’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year three times. Under Donald’s guidance, Resverlogix was honored with multiple awards, the most prestigious being the 2008 World Economic Forum (WEF) Technology Pioneer award in Davos Switzerland. He has also arranged support for several non-profit organizations, including the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.
DR. EWELINA KULIKOWSKI, PH.D.
Senior Vice President of Research & Development
Dr. Kulikowski has over 11 years experience in scientific research and drug development. Dr. Kulikowski joined Resverlogix in 2005 as Director of Research and Development and has been involved in the development of lead drug RVX-208 (apabetalone) from its discovery through to the IND and into clinical development. Dr. Kulikowski has led projects in oncology, ophthalmology, and vascular inflammation, as well as served as a liaison between the science and business teams. As Director of Business Development and Scientific Affairs, Dr Kulikowski was involved in various aspects of pipeline development including market, reimbursement and pharmacoeconomic surveys, regulatory affairs, commercial and lifecycle management. Most recently, Dr. Kulikowski has led the Neurodegenerative Program and continues to oversee this area of development. In 2004, she received her Doctorate in Oncology from the University of Calgary, AB.
DR. NORMAN C.W. WONG, M.D., FRCP
Chief Scientific Officer & Co-Founder
Dr. Wong's research interest focus is on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus. His clinical interest encompasses patients with thyroid disease or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression.
Dr. Wong keeps active in the academic community with speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.
A. BRAD CANN, CA
Chief Financial Officer
Brad has more than 19 years of financial and business experience. Prior to joining Resverlogix, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust, a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second largest hotel REIT. Brad joined Royal Host in January 2004 and held a number of senior positions and was appointed Chief Financial Officer in May 2007 and Executive Vice President in January 2008. Brad's responsibilities included financial reporting, accounting, taxation, investor relations, payroll, information technology and internal audit. As acting Co-Chief Executive Officer of Royal Host, Brad shared responsibility for developing the strategic initiatives of the Trust and leading its executive team in day-to-day operations, as well as investing, financing and real estate transactions.
Prior to joining Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company and Chief Financial Officer of an oilfield waste water treatment company. Prior thereto, Brad held various positions with a chartered accounting firm.
Brad is a Chartered Accountant and a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.
DR. JAN O. JOHANSSON, M.D., PH.D.
Senior Vice President Medical Affairs
Dr. Johansson has had a distinguished 30 plus year career of which the past 18 years have been in small biotechnology and large pharmaceutical companies with expertise in the cardiovascular disease therapeutic area. He has served as Chief Medical Officer at Nuvelo, Inc., VP, Clinical Research and Development at Lipid Sciences, Inc. and was Co-founder, VP, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. From 1995 to 1997, Dr. Johansson was a medical adviser with executive responsibilities at Pharmacia bringing one lipid lowering product to the market and heading the apolipoproteinA-IMilano clinical program.
Dr. Johansson earned his M.D. and Ph.D. at the Karolinska Institute in Sweden where he lead a successful career as a tenured associate professor at the Karolinska Hospital and as a practicing physician. He has published more than 50 peer-review medical articles, and is a member of several scientific organizations including the American Heart Association and the European Atherosclerosis Society.
DR. MICHAEL SWEENEY, M.D.
Senior Vice President of Clinical Development
Dr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications.
Dr. Sweeney has an impressive career history, spanning over 26 years in the pharmaceutical industry. This includes 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of Marketing of the Viagra® Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was Chief Medical Officer and Vice President of Research and Development at Depomed, Inc. in Silicon Valley. Dr. Sweeney was also the Vice President of Medical Affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa® for patients with cardiovascular disease and chronic angina.
Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He is a fellow of the Royal College of Physicians of Edinburgh.
KENNETH LEBIODA, BA
Senior Vice President Business & Corporate Development
Ken has over 25 years experience in the innovative pharmaceutical industry with leading global companies such as Bristol-Myers Squibb, Hoechst Marion Roussel and Marion Merrell Dow. He held a variety of management positions with these companies in the areas of sales and business development, regulatory affairs, reimbursement and market access. Ken's past contributions in helping build leading global cardiovascular brands such as Plavix, Pravachol, Cardizem, and Avapro will provide strategic guidance for the company's technologies in the areas of market analysis, regulatory affairs, pharmacoeconomics, licensing and commercial development.
DR. HENRIK C. HANSEN, PH.D.
Vice President of Intellectual Property
Henrik C. Hansen joined Resverlogix in 2005 and currently holds the position of VP of Intellectual Property. Henrik has more than 13 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include medicinal chemistry and carbohydrate chemistry, process development, and manufacturing of drug substances and drug products under cGMP for clinical use.
Henrik holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 40 articles and meeting abstracts and is listed as inventor of 9 patent families.
Vice President of Investor Relations
Clayton brings 15 years of capital markets and investor relations experience to Resverlogix. Most recently, Clayton led the investor relations function for one of Canada’s largest energy companies with shareholders and joint venture partners geographically dispersed throughout North America, Europe and Asia. Prior to his career in investor relations, Clayton worked for two of Canada’s largest financial institutions in equity research as an energy specialist, one of which was a number one ranked Royalty Trust Research Team (Brendan Wood Survey 2005).
Clayton’s strengths lie in his ability to engage a community through effective communications, navigate complex systems and strategic transitioning. His efforts in investor relations have been recognized by industry and peers through recognition of being amongst the top five companies in Canada for the “Most Progress in Investor Relations” twice in his career in the IR Magazine Investor Perceptions Study.
Clayton is a member of the Canadian Investor Relations Institute (CIRI) and holds an MBA – Finance from the University of Calgary and Bachelor of Management from the University of Lethbridge.